Florida Sharkman Protocol: Powerful Fenbendazole & Ivermectin Cycle

Florida Sharkman Protocol

Quick Overview

• Author: Anonymous individual or group known as “Florida Sharkman”
• Goal: Multi-compound antiparasitic and antimicrobial approach explored by some individuals with cancer and other conditions
• Duration: 30-day primary cycle (Protocol A), with optional follow-on protocols
• Key compounds: Fenbendazole, Ivermectin, Doxycycline, Berberine, Oxfendazole, Moxidectin
• Supporting supplements: Curcumin, Quercetin, Vitamin E succinate (referenced in some versions of the protocol)
• Evidence base: Preclinical laboratory data and anecdotal reports only — no clinical trial of the combined regimen exists

Overview

The Florida Sharkman Protocol is an anonymously developed, community-sourced regimen published at floridasharkman.org. It was created by an individual or group using the pseudonym “Florida Sharkman” and made publicly available in its current form on October 29, 2024. The protocol combines antiparasitic agents, a broad-spectrum antibiotic, and botanical compounds in a staged schedule intended to target cancer, parasitic infections, and related conditions.

The regimen draws on the hypothesis, explored in preclinical research, that certain antiparasitic and antimicrobial drugs may have activity against cancer cells through mechanisms distinct from conventional chemotherapy. Compounds such as fenbendazole, ivermectin, and doxycycline have each been the subject of independent laboratory research examining their potential anti-cancer properties. The Florida Sharkman Protocol combines these agents into a structured sequence based on the originator’s interpretation of that research.

The protocol has circulated widely in online patient communities and forums. It is not affiliated with any clinical institution, has not been evaluated in formal clinical trials as a combined regimen, and should be regarded as an experimental community protocol. Individuals considering it should read the information at floridasharkman.org directly and consult a qualified healthcare professional before proceeding.

Who Is “Florida Sharkman”? The Anonymity Problem

Unlike named protocols associated with a specific clinician, patient, or clinic — such as the Joe Tippens protocol or the Care Oncology Clinic regimen — the Florida Sharkman Protocol has no publicly identified author. The name is a pseudonym, and the website provides no verifiable credentials, institutional affiliation, or professional qualifications behind the recommendations.

This anonymity matters for several reasons. First, there is no accountable party who can be questioned about how the doses were chosen, what safety data (if any) were reviewed, or why particular compounds were combined. Second, there is no track record: readers cannot evaluate the author’s medical training, prior claims, or conflicts of interest. Third, anonymous protocols cannot be corrected or retracted in the way a peer-reviewed publication can. When a regimen recommends multiple prescription-only drugs at doses well above their approved ranges, the absence of an identifiable, credentialed author is a significant red flag rather than a neutral detail.

None of this means every element of the protocol is baseless — the individual compounds do have published preclinical research behind them. But it does mean that the specific schedule, doses, and combinations represent one anonymous author’s interpretation, not a consensus of oncologists or a validated clinical framework. That distinction is central to reading the protocol responsibly.

Dosage and Schedule — Protocol A

Protocol A is the primary 30-day cycle. The schedule is divided into phases, with compounds introduced and removed at specific intervals. The dosages below are as published on the originating website and are reproduced here for documentation and critical analysis — not as a recommendation to follow them.

Dosing Notes

• Berberine: Taken with meals to reduce gastrointestinal side effects.
• Doxycycline: Taken on an empty stomach with a full glass of water; the user is advised to remain upright for at least 30 minutes to avoid esophageal irritation.
• Fenbendazole: Taken with the largest meal of the day, because it is a poorly water-soluble compound whose absorption improves with dietary fat.
• Ivermectin: Taken on an empty stomach for consistent absorption.
• Oxfendazole: Taken with a fatty meal to enhance bioavailability.
• Moxidectin: No specific food timing noted in the published protocol.

Note that the published fenbendazole dose of 50 mg/kg is dramatically higher than the doses used in most human anecdotal protocols (commonly 222 mg–1 g per day). For a 70 kg adult, 50 mg/kg equals roughly 3.5 grams in a single evening dose — a figure that should be viewed with considerable caution given the documented dose-dependent liver injury discussed later in this article.

The Logic of Drug Rotation — Does Cycling Actually Make Sense?

The defining feature of the Florida Sharkman Protocol is rotation: rather than taking one compound continuously, it stages different agents in and out over the cycle. Fenbendazole runs in week one, ivermectin in week two, oxfendazole and moxidectin appear later, and berberine runs throughout. The stated rationale — consistent with how many patient-led protocols describe cycling — rests on three ideas.

1. Preventing adaptation and resistance. Cancer cells are notorious for adapting to sustained selective pressure. In theory, rotating agents that hit different targets makes it harder for a resistant subpopulation to expand, because the “escape route” from one drug may be blocked by the next. This mirrors the logic of combination chemotherapy, where multiple mechanisms are used together to reduce the odds of resistance. The critical difference is that chemotherapy combinations are validated in trials that establish which drugs, doses, and sequences are actually synergistic — whereas this protocol’s rotation is theoretical.

2. Managing cumulative toxicity. Spacing agents out is also framed as a way to give the body — particularly the liver — recovery time between exposures. This is a reasonable instinct, but it is undermined by the overlaps built into the schedule: doxycycline runs continuously for two weeks, berberine runs for the full 30 days, and oxfendazole (a benzimidazole, like fenbendazole) is introduced only a few days after the fenbendazole week. Because oxfendazole is actually the active metabolite of fenbendazole, the “rotation” between them is less of a mechanistic switch than it appears.

3. Covering multiple metabolic pathways. The compounds are chosen to attack several vulnerabilities at once: microtubules (benzimidazoles), oncogenic signaling and efflux pumps (avermectins), mitochondrial function (doxycycline), and energy metabolism (berberine). On paper this is a multi-hallmark strategy. In practice, whether the concentrations achievable in a human being at these oral doses ever reach the levels required to engage those targets is the central unanswered question — and it is a question the protocol does not address.

In short, the rotation concept borrows real principles from oncology, but applies them without the validation that makes those principles safe. A plausible-sounding rationale is not the same as evidence that the specific rotation works or is safe.

Mechanism of Action

The compounds in this protocol have each been investigated independently in preclinical settings. The summaries below reflect findings from laboratory research and do not constitute evidence of clinical efficacy in humans when the agents are used as a combined regimen.

Fenbendazole

Fenbendazole is a benzimidazole anthelmintic that binds to β-tubulin, the protein subunit of microtubules. In cancer cell lines it acts as a moderate microtubule-destabilizing agent, disrupting the mitotic spindle and arresting cells in the G2/M phase of division. Research by Dogra and colleagues (2018) demonstrated that fenbendazole also causes mitochondrial translocation of p53 and inhibits glucose uptake by downregulating GLUT transporters and hexokinase II, a key glycolytic enzyme. This combination of microtubule disruption and glucose starvation represents its proposed anti-cancer mechanism at the cellular level. Its major limitation is pharmacokinetic: fenbendazole is poorly water-soluble, and oral bioavailability in humans is low and saturable, making it difficult to reach the concentrations that produce these effects in a dish.

Ivermectin

Ivermectin is a macrocyclic lactone antiparasitic studied in cancer models for several distinct mechanisms. It promotes proteasome-dependent degradation of PAK1 (p21-activated kinase 1), a kinase frequently overexpressed in tumors and linked to proliferation, drug resistance, and metastasis. Studies published in 2024 and 2025 confirm that ivermectin downregulates PAK1 in lung adenocarcinoma, triggering autophagy and apoptosis, and that it suppresses the Wnt/β-catenin pathway by downregulating Wnt5a/b and LRP6 in endocrine-resistant breast cancer cells — reducing markers of epithelial-to-mesenchymal transition such as vimentin and Snail. Ivermectin also inhibits the P-glycoprotein (MDR1) efflux pump, which is one mechanism by which tumors resist chemotherapy, and it can induce oxidative stress and mitochondrial-dependent apoptosis. As with fenbendazole, the anti-cancer concentrations used in vitro substantially exceed the plasma levels considered safe in humans.

Doxycycline

Doxycycline is a tetracycline-class antibiotic used off-label here for its effects on mitochondria. Because mitochondria evolved from bacteria, an antibiotic that targets the bacterial 70S ribosome also inhibits mitochondrial protein translation. Research published in Oncotarget showed that doxycycline targets cancer stem cells by suppressing mitochondrial biogenesis — reducing the expression of mitochondrial DNA-encoded proteins, lowering oxidative capacity, and pushing surviving cells toward glycolytic metabolism. Lamb and colleagues (2015) described this approach as “treating cancer like an infectious disease,” reporting that doxycycline reduced stemness markers such as CD44 and ALDH1 and inhibited mammosphere formation across multiple tumor types.

Berberine

Berberine is a plant-derived isoquinoline alkaloid with well-documented metabolic effects. Its proposed anti-cancer activity is linked primarily to activation of AMP-activated protein kinase (AMPK), an energy-sensing enzyme that suppresses anabolic metabolism and proliferation. Berberine activates AMPK, inhibits mTOR signaling, and suppresses the Warburg effect (aerobic glycolysis), restricting both glucose and lipid fuel lines. It has also been identified as a candidate for targeting glycolysis-dependent, doxycycline-resistant cancer stem cells — a mechanistic rationale for pairing it with doxycycline. Berberine itself has poor oral bioavailability and is a known modulator of CYP enzymes, which is relevant to the interaction concerns below.

Oxfendazole

Oxfendazole is a benzimidazole structurally related to fenbendazole — in fact, it is the primary active metabolite that the liver produces from fenbendazole via CYP450 enzymes. Like other benzimidazoles it binds tubulin and disrupts microtubule polymerization. It has been studied separately in human safety trials and shows a somewhat different systemic exposure profile than the parent compound. Its inclusion on days 17–19 follows the same mechanistic logic as fenbendazole; because it is fenbendazole’s own metabolite, however, it does not represent a genuinely different mechanism of action.

Moxidectin

Moxidectin is a long-acting macrocyclic lactone antiparasitic of the milbemycin class, structurally related to ivermectin. It acts on glutamate-gated chloride channels in parasites and has been explored in limited preclinical contexts for potential anti-cancer activity. Its inclusion on Day 23 appears intended to extend avermectin-class coverage later in the cycle. The clinical evidence for moxidectin in oncology is considerably thinner than for ivermectin, and its long half-life means it lingers in the body far longer than the single dose might suggest.

Compound Comparison at a Glance

The table below summarizes the drug class, proposed anti-cancer mechanism, regulatory status, and the principal practical limitation of each agent in the protocol.

The Supporting Supplement Stack

Some versions of the Florida Sharkman regimen and closely related community protocols add botanical supplements — most commonly curcumin, quercetin, and vitamin E succinate — alongside the core drugs. These are included on the rationale that they may enhance absorption of the other agents or contribute their own metabolic effects.

Curcumin, the principal curcuminoid in turmeric, has been studied extensively for potential effects on cell-cycle regulation, apoptosis, and angiogenesis. Its central problem, according to the U.S. National Cancer Institute’s summary, is very low oral bioavailability: even at doses up to 8,000 mg/day, free curcumin plasma concentrations remain low. Quercetin, a flavonoid, is often paired with curcumin precisely because it can act as a bioavailability enhancer, slowing curcumin’s metabolism. Vitamin E succinate (and its water-soluble derivative TPGS, d-α-tocopheryl polyethylene glycol succinate) is used in some formulations both for its own reported pro-apoptotic activity and as a solubilizing co-formulant that improves delivery of poorly soluble compounds.

It is important to be clear about the evidence: the NCI states that current data are inadequate to recommend curcumin, alone or as an adjuvant, for cancer treatment outside controlled trials, and it specifically flags liver-toxicity concerns with some commercial curcumin products. Adding supplements does not neutralize the risks of the prescription drugs in the protocol, and some — like quercetin, which also affects drug-metabolizing enzymes — can themselves alter how the other compounds are processed.

The Cumulative Toxicity Problem

The single biggest safety concern with a multi-drug protocol like this is not any one compound in isolation — it is the cumulative burden on the liver, which must metabolize nearly every agent involved. Fenbendazole in particular has a growing record of documented liver injury when used off-label at high doses.

Published case reports describe a consistent pattern of dose-dependent hepatocellular injury:

• A 2024 case documented severe drug-induced liver injury in a patient who self-administered roughly 9 grams of fenbendazole per week for a year; a liver biopsy confirmed centrilobular hepatocyte necrosis. Liver function recovered fully within three months of stopping.
• A 2026 case involving a patient on immunotherapy showed severe hepatotoxicity after escalating fenbendazole from an intermittent schedule to a daily dose, with rapid improvement once the drug was discontinued.
• An earlier 2021 report in an 80-year-old patient on pembrolizumab described asymptomatic liver-enzyme elevations on a 3-on/4-off gram-level schedule, resolving within seven weeks of cessation.

The proposed mechanisms include oxidative stress and glutathione depletion during hepatic metabolism, production of toxic intermediates, direct microtubule-related impairment of hepatocyte architecture and bile secretion, and — critically for cancer patients — interaction with immune checkpoint inhibitors, which can make it very hard to distinguish drug-induced injury from immunotherapy-related hepatitis. Because fenbendazole’s first-pass metabolism is saturable, the relationship between dose and liver exposure is not linear, and individual responses vary with genetics, diet, and other medications.

Now layer that onto a protocol that also runs two weeks of doxycycline (which carries its own hepatic and photosensitivity considerations), continuous berberine (a CYP modulator), plus oxfendazole and moxidectin. The theoretical benefit of “rotation” giving the liver a rest is difficult to reconcile with a schedule that keeps at least one hepatically processed compound in play almost every single day of the cycle. Anyone considering such a regimen would need frequent liver-function monitoring at minimum — a point the protocol itself does not adequately emphasize.

The Drug-Interaction Web

Combining several prescription drugs, an antibiotic, and enzyme-modulating botanicals creates a dense web of possible interactions. Two shared pathways dominate the concern: the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp / MDR1) efflux transporter.

Ivermectin is metabolized primarily by CYP3A4 and is both a substrate and inhibitor of P-glycoprotein. This means any co-administered CYP3A4 inhibitor (many common medications qualify) can raise ivermectin levels, while berberine and quercetin — both present in the supplement stack — can themselves shift CYP activity in ways that are hard to predict when stacked. Doxycycline’s absorption is reduced by calcium, antacids, and possibly berberine taken at the same time. And for any patient on an anticoagulant such as warfarin, ivermectin may increase INR and bleeding risk. A pharmacist or physician should review the entire medication and supplement list before any such regimen is considered — a step that is impossible to do responsibly when following an anonymous protocol alone.

What the Evidence Actually Shows

It is worth stating plainly what does and does not exist in the evidence base. The individual compounds have real, published preclinical research — cell-line and animal studies showing plausible anti-cancer mechanisms. There are also compilations of patient-reported outcomes: one widely cited collection documents more than 760 self-reported cases across roughly 31 cancer subtypes, including instances of complete or partial responses, often in patients with advanced disease who had also received conventional therapy.

What does not exist is any randomized controlled trial — or indeed any prospective clinical trial — of the Florida Sharkman Protocol, or of most of these drug combinations, in humans with cancer. The anecdotal reports are hypothesis-generating, not proof. They are subject to well-known biases: survivorship bias (people who do poorly stop reporting), publication and selection bias (positive stories spread; negative ones do not), and confounding from concurrent standard-of-care treatment, which makes it impossible to attribute any improvement to the protocol itself. A significant part of the reason rigorous trials have not been run is commercial: these are off-patent drugs, so there is little financial incentive for industry-funded Phase III studies — but the absence of a profit motive is not the same as proof that the drugs work.

The honest summary is that the science behind the components is genuinely interesting and worth continued formal investigation, while the specific anonymous, high-dose, multi-drug protocol built on top of that science is unproven and carries real, documented risks.

Additional Protocol Variations

The Florida Sharkman website describes several additional protocols beyond Protocol A:

• Antiviral Protocol: A variant designed for virus-associated conditions, listed as a precursor or adjunct to Protocol B.
• Protocol B: A follow-on protocol recommended if infection is not cleared or for virus-caused cancers, following a two-week break after Protocol A or the Antiviral Protocol.
• Protocol C: An additional sequential protocol published on the website.
• Brain Cancer (GBM) Protocol: A variant specifically adapted for glioblastoma multiforme, taking blood-brain barrier considerations into account — a notable point given that P-gp inhibition (from ivermectin) can increase CNS drug penetration.
• Lyme Disease Protocol: A variant tailored for Lyme disease and related tick-borne illness.

Full details of each variant are available at floridasharkman.org/protocol/protocol/. The proliferation of condition-specific variants — cancer, viral illness, glioblastoma, Lyme — from a single anonymous source, without trial data for any of them, reinforces the importance of professional medical oversight rather than self-directed use.

Monitoring and Harm Reduction

For anyone who, despite the lack of validation, chooses to explore any part of this protocol, doing so only under the supervision of a qualified oncologist is essential. Reasonable monitoring — the kind an informed physician would insist on — would include at minimum:

• Baseline and regular liver function tests (AST, ALT, bilirubin) given the documented, dose-dependent hepatotoxicity of fenbendazole, with prompt discontinuation if enzymes rise.
• A full medication and supplement reconciliation by a pharmacist to screen for CYP3A4 and P-gp interactions before starting.
• Extra caution with immunotherapy: patients on checkpoint inhibitors face a real risk of confounded liver injury and should not add hepatotoxic compounds without oncology input.
• Avoiding dose escalation: rapid increases in fenbendazole dosing are identified in the literature as a primary trigger for severe injury.
• Not substituting for standard care: the greatest danger of any unproven protocol is that it delays or replaces treatment with a real chance of benefit.

Important Considerations

This protocol has not been evaluated in formal clinical trials as a combined regimen. The information presented is for educational purposes only. Always consult a qualified healthcare professional before starting any new treatment protocol.

The Florida Sharkman Protocol is an anonymous community-developed regimen with no identified author, no peer review, and no institutional affiliation. It should not be treated as a clinically validated treatment. The compounds have been studied in preclinical (cell and animal) models; this does not establish efficacy in humans.

Multiple prescription medications are included. Doxycycline, ivermectin, oxfendazole, and moxidectin all require a prescription in most jurisdictions and must be used under medical supervision. Using prescription medications without oversight presents serious safety risks.

High-dose fenbendazole at 50 mg/kg is far above the doses used in most human anecdotal protocols and vastly above any veterinary indication for its intended use. The safety of this dose in humans is not established, and published case reports link high-dose fenbendazole to serious liver injury.

Anyone using this or any protocol of this nature should be doing so under the care of an oncologist or other qualified physician who is aware of all medications being taken.

Sources